Patheon® is a leading provider of drug substance and drug product services for the global biopharmaceutical industry. SEE AND Read More »

Want to learn more?

Patheon Overview Brochure

History and Milestones


January Appoint Dr. Aqeel Fatmi as Executive Vice President, Global Research & Development and Chief Scientific Officer  


December Acquire Banner Pharmacaps, a market leader in soft gelatin capsule technology, adding a new proprietary products and technology business.  Appoint Geoff Glass as President, Product and Technology Commercialization 

November Appoint Michael Lehmann as President, Global PDS

October Appoint Harry Gill as Senior Vice President, Quality and Continuous Improvement

April Launch P-Gels™ line of softgel development and manufacturing services, a partnership with Softigel offering 9 billion capsule available capacity.

March Launch Patheon Certified Consultants program giving customers access to 15 of the industry's top independent consultants.

February Appoint Stuart Grant as Executive Vice President, Chief Financial Officer.

January Appoint Antonella Mancuso as President, Global Commercial Operations and Chief Manufacturing Officer.


October Sign three-year, $18 million development agreement with Boehringer Ingelheim.

September Establish South San Francisco Lab early development center.

August Appoint Rebecca Holland New as Chief Human Resources Officer and Senior Vice President, HR and Corporate Communications 

July Appoint Gary L. Shope as Chief of Staff.

May Appoint Michael E. Lytton as Executive Vice President, Corporate Development and Strategy, and General Counsel.

March Launch the first backup manufacturing program for sterile products.

February Appoint James C. Mullen as Chief Executive Officer and to Board of Directors.

January Launch SoluPath™, the first fixed-price, multi-platform solution to improve bioavailability.


December Appoint Peter Bigelow as President, North American Operations and Interim Chief Executive Officer.

October Receive 2010 European Outsourcing Award for the most effective scale-up/technology transfer.

June Expand manufacturing agreement with Merck & Co., solidifying Patheon as a key preferred supplier, serving the company from eight global facilities.

May Receive 2010 Lilly Sustained Supplier Award for Bourgoin facility's continued delivery of exemplary quality, speed and service.

April Add Softgel development and manufacturing capability to Cincinnati facility.

April Appoint Mark Kontny, Ph.D. as President, Global Pharmaceutical Development Services and Chief Scientific Officer.

March Sign long-term agreement for commercial manufacturing of Contrave® (sustained-release obesity drug), and development of future formulations of Orexigen® products.

January Announce two five-year manufacturing agreements with Sanofi-Aventis.


November Expand Ferentino, Italy site, adding a sterile pilot plant within a development center, focusing the facility on sterile manufacturing, including aseptically filled, terminally sterilized liquids and lyophilization.

December First commercial shipments of SUMAVEL® DosePro® (sumatriptan injection) to Zogenix®.


September Establish U.S. headquarters in Research Triangle Park, North Carolina, and European headquarters in Zug, Switzerland.


November Appoint Wesley P. Wheeler as Chief Executive Officer

April JLL Partners, through its investment vehicle JLL Patheon Holdings LLC, complete the purchase of $150 million of convertible preferred shares of Patheon through a private placement.


January Sign five-year master supply agreement with Merck & Co as a strategic partner for commercial manufacturing and pharmaceutical development services


December Acquire MOVA Pharmaceutical Corporation (MOVA), a leading U.S. prescription pharmaceutical contract manufacturer located in Puerto Rico, U.S. MOVA comprised three U.S. FDA-approved facilities, with over 900,000 ft2 (83,600 m2) of solid, liquid, sterile liquid and solid oral cephalosporin manufacturing capacity.


December Acquire Cincinnati Operations from Aventis (now Sanofi-Aventis). The facility, Patheon's first in the United States, included 372,000 ft2 (34,500 m2) of manufacturing and 85,000 ft2 (7,900 m2) dedicated to development, expanding PDS capacity.

February Acquire Ferentino Operations outside Rome, Italy, expanding lyophilization capacity and adding Large Volume Parenteral (LVP) manufacturing capabilities. Lyophilization capacity expanded with significant upgrades to Ferentino and Monza Operations.


June Establish PDS facility in Swindon, U.K., enabling integrated development services in both Europe and North America, and adding sterile injectable development capabilities.

May Acquire Whitby Operations from Novartis Pharmaceuticals Canada. The 193,000 ft2 (17,900 m2) facility increases capacity to manufacture high-volume prescription and OTC products.

March Open newly constructed 8,500 ft2 (800 m2) formulation development facility at Toronto Region Operations, expanding PDS capacity and high-potency development capabilities.


September Acquire remaining 52% of the shares of Global Pharm Inc.


December Acquire two European facilities from Hoechst Marion Roussel Group: Swindon Operations, U.K. and Bourgoin-Jallieu Operations, France. Strengthens European presence with significant increase in prescription manufacturing capacity, and addition of sterile injectable and cephalosporin capabilities.


November Acquire 300,000 ft2 (27,900 m2) facility in Monza, Italy. The former Boehringer Mannheim facility enables offering of sterile injectable and lyophilized product services.


January Acquire Toronto Region Operations facility in Mississauga, Canada from Hoffman-La Roche Ltd (former Syntex facility). The 184,000 ft(17,100 m2) facility included high-potency capacity for prescription products and modern laboratory facilities to expand pharmaceutical development services (PDS) business. The facility also offered U.S. FDA-approved manufacturing capabilities.


November Complete fully marketed public offering, raising gross proceeds of C$14.4 million by issuing 11.5 million common shares for C$1.25 per share.


May Enter prescription and clinical trial materials manufacturing by acquiring 48% ownership of Global Pharm Inc. The facility, later renamed Toronto York Mills Operations, had U.S. FDA-approved manufacturing capabilities and was formerly owned by Upjohn of Canada.


Add facility in Burlington, Canada, later renamed Burlington Century Operations.


May Change company name to Patheon Inc. (Stock symbol: PTI).

January Become publicly traded company on the Toronto Stock Exchange.


Begin providing pharmaceutical manufacturing services to the U.S. market, capitalizing on the North American Free Trade Agreement (NAFTA).


Expand operations to Burlington, Canada by forming Promix Laboratories Inc. Facility later renamed Burlington Gateway Operations.


Contract pharmaceutical manufacturing business established as Custom Pharmaceuticals Ltd.

Ask The Experts

Anil Kane, Ph.D., MBA

Anil Kane, Ph.D., MBA
Dr. Kane has more than 25 years of experience in the science and business of taking molecules throug
Read More »

Kaspar van den Dries, Ph.D.

Kaspar van den Dries, Ph.D.
Based at our Tilburg facility in the Netherlands, Dr. van den Dries leads Patheon’s European researc
Read More »

Jason Vaughn, Ph.D.

Jason Vaughn, Ph.D.
Dr. Vaughn has expertise in early and preclinical development of liquid, semi-solid and solid dosage
Read More »

Roman Hlodan, Ph.D.

Roman Hlodan, Ph.D.
Dr. Hlodan is an expert in the development of biopharmaceuticals, including analytical method devel
Read More »

Stephen Closs

Stephen Closs
Mr. Closs possess more than 23 years of experience in formulation development, tech transfer, scale-
Read More »

William E. Weiser, Ph.D.

William E. Weiser, Ph.D.
Dr. Weiser is an expert in analytical method development and validation for APIs and drug products.
Read More »

View All »

Knowledge Library

Please fill the below form to access requested content

First Name

Last Name





Address Line 1

Address Line 2


Zip/ Postal Code